Testing effectiveness (Phase 2)Not Yet RecruitingNCT07793253
What this trial is testing
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Who this might be right for
Biliary Tract CancersIntrahepatic Cholangiocarcinoma (Icc)Extrahepatic Cholangiocarcinoma+3 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 55